DOI QR코드

DOI QR Code

Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy with or without Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: Meta-analysis of 1,096 Patients from 11 Randomized Controlled Trials

  • Liang, Zhong-Guo (Department of Radiation Oncology, Cancer Hospital of Guangxi Medical University, Cancer Institute of Guangxi Zhuang Automomous Region) ;
  • Zhu, Xiao-Dong (Department of Radiation Oncology, Cancer Hospital of Guangxi Medical University, Cancer Institute of Guangxi Zhuang Automomous Region) ;
  • Tan, Ai-Hua (Department of Radiation Oncology, Cancer Hospital of Guangxi Medical University, Cancer Institute of Guangxi Zhuang Automomous Region) ;
  • Jiang, Yan-Ming (Department of Radiation Oncology, Cancer Hospital of Guangxi Medical University, Cancer Institute of Guangxi Zhuang Automomous Region) ;
  • Qu, Song (Department of Radiation Oncology, Cancer Hospital of Guangxi Medical University, Cancer Institute of Guangxi Zhuang Automomous Region) ;
  • Su, Fang (Department of Radiation Oncology, Cancer Hospital of Guangxi Medical University, Cancer Institute of Guangxi Zhuang Automomous Region) ;
  • Xu, Guo-Zeng (Department of Radiation Oncology, Cancer Hospital of Guangxi Medical University, Cancer Institute of Guangxi Zhuang Automomous Region)
  • Published : 2013.01.31

Abstract

Purpose: To evaluate the efficacy and toxicity of induction chemotherapy followed by concurrent chemoradiotherapy (the treatment group) versus concurrent chemoradiotherapy with or without adjuvant chemotherapy (the control group) for locoregionally advanced nasopharyngeal carcinoma. Methods: The search strategy included Pubmed, Embase, the Cochrane Library, China National Knowledge Internet Web, Chinese Biomedical Database and Wanfang Database. We also searched reference lists of articles and the volumes of abstracts of scientific meetings. All randomized controlled trials were included for a meta-analysis performed with RevMan 5.1.0. The Grading of Recommendations Assessment, Development, and Evaluation system (GRADE) was used to rate the level of evidence. Results: Eleven studies were included. Risk ratios of 0.99 (95%CI 0.72-1.36), 0.37 (95%CI 0.20-0.69), 1.08 (95%CI 0.84-1.38), 0.98 (95%CI 0.75-1.27) were observed for 3 years overall survival, 3 years progression-free survival, 2 years loco-regional failure-free survival and 2 years distant metastasis failure-free survival. There were no treatment-related deaths in either group in the 11 studies. Risk ratios of 1.90 (95%CI 1.24-2.92), 2.67 (95%CI 0.64-11.1), 1.04 (95%CI 0.79-1.37), 0.98 (95%CI 0.27-3.52) were found for grade 3-4 leukopenia, grade 3-4 thrombocytopenia, grade 3-4 mucous membrane, and grade 3-4 hepatic hematologic and gastrointestinal toxicity, the most significant toxicities for patients. Conclusion: Compared with the control group, induction chemotherapy followed by concurrent chemoradiotherapy was well tolerated but could not significantly improve prognosis in terms of overall survival, loco-regional failure-free survival or distant metastasis failure-free survival.

References

  1. Zhang L, Zhao C, Ghimire B, et al (2010). The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials. BMC Cancer, 10, 558. https://doi.org/10.1186/1471-2407-10-558
  2. Zhong WH, Feng HX, Jiang HH, Zhang LP (2011). Clinical observation and nursing of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy with or without adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Chin Med Innov, 20, 162-4.
  3. He AJ (2011). Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma. Hebei Med J, 33, 2115-6.
  4. He QD, Yang L, Nie YH,Kang HB (2009). A phase $\phi$o study of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma. Chin Clin Oncol, 14, 1011-4.
  5. Heng DM, Wee J, Fong KW, et al (1999). Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer, 86, 1912-20. https://doi.org/10.1002/(SICI)1097-0142(19991115)86:10<1912::AID-CNCR6>3.0.CO;2-S
  6. Julian PTH and Sally G (2011). Cochrane handbook for systematic review of interventions version 5.0.1[updated March 2011].The cochrane collaboration 2011,available from www.cochranehandbook.org.
  7. Huang S, Deng G, Huang G, et al (2012). Efficacy of induction chemotherapy combined with concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma. Chin J Clin Oncol, 39, 788-91.
  8. Hui EP, Ma BB, Leung SF, et al (2009). Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol, 27, 242-9. https://doi.org/10.1200/JCO.2008.18.1545
  9. Ma HM, Yuan X, Huang YL, Lin YF, Liu CX (2009). Paclitaxel and cisplatin, 5-fluorouracil (TPF) programme neoadjuvant chemotherapy for advanced nasopharyngeal carcinoma. Mod Oncol, 17, 1233-5.
  10. Ruste SA, Dizon DS, Ramirez F, et al (2011). Induction chemotherapy followed by concurrent chemoradiotherapy vs concurrent chemoradiotherapy followed by chemotherapy in the treatment of patients with advanced nasopharyngeal carcinoma. Phil J Intern Med, 49, 1-7.
  11. Sun R (2009). Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy with or without adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma [master].
  12. Teo P, Yu P, Lee WY, et al (1996). Significant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinoma evaluated by computer tomography. Int J Radiat Oncol Biol Phys, 36, 291-304.
  13. Wang XJ, Shou T, Diao XM, et al (2011). Neoadjuvant chemotherapy with vinorelbine followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma. J Pract Med, 27, 4451-3.
  14. Xu MJ, Ye JM, Wu LQ,Wang XC (2011). Study of TPF neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with cisplatin in locally advanced nasopharyngeal carcinoma. J Pract Oncol, 26, 291-4.
  15. Yamazaki T, Ishiki H, Okano S, et al (2011). Impact of induction chemotherapy on local control for locally advanced nasopharyngeal cancer. Eur J Cancer, 47, S569.
  16. Yu H-S, Wang X, Song AQ, et al (2012). Concurrent chemoradiotherapy versus radiotherapy alone for locoregionally advanced nasopharyngeal carcinoma. Asian Pacific J Cancer Prev, 13, 3961-5. https://doi.org/10.7314/APJCP.2012.13.8.3961
  17. Zeng XT, Leng WD, Li S, Guo Y, Wang P (2011). How to understand and use GRADE system correctly? A brief outline. Chin J Evid-Based Med, 11, 985-90.
  18. Al-Sarraf M, LeBlanc M, Giri PG, et al (1998). Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol, 16, 1310-7.
  19. Chan AT, Teo PM,Johnson PJ (2002). Nasopharyngeal carcinoma. Ann Oncol, 13, 1007-15. https://doi.org/10.1093/annonc/mdf179
  20. Chan AT, Hui E, Ma B, et al (2005). A randomized phase II study of concurrent cisplatin-radiotherapy (RT) with or without neoadjuvant chemotherapy using docetaxel (Taxotere) and cisplatin in advanced nasopharyngeal carcinoma (NPC). 41st Annual Meeting of the American Society of Clinical Oncology (ASCO), J Clin Oncol, Abstract No. 5544.
  21. Chen XJ, Qiu RL, Yang CL, Liu YQ (2012). Study of TPF neoadjuvant chemotherapy followed by concurrent intensity modulated radiochemotherapy in the treatment for 30 cases with locally advanced nasopharyngeal carcinoma. Chin J Clin Oncol Rehabil, 19, 201-4.
  22. Cui JD, Long GN, Zhang Y, et al (2012). Study of TPF neoadjuvant chemotherapy followed by concurrent intensity modulated radiochemotherapy in the treatment for 30 cases with locally advanced nasopharyngeal carcinoma. Chin Clin Oncol, 17, 524-9.
  23. Fong KW, Chua EJ, Chua ET, et al (1996). Patient profile and survival in 270 computer tomography-staged patients with nasopharyngeal cancer treated at the Singapore General Hospital. Ann Acad Med Singapore, 25, 341-6.
  24. Fountzilas G, Ciuleanu E, Kalogera-Fountzila A, et al (2009). Induction chemotherapy (IC) followed by concomitant chemoradiotherapy (CCRT) versus CCRT alone in patients with locally advanced nasopharyngeal carcinoma (LA-NPC) - A randomized phase II study of the Hellenic Cooperative Oncology Group. Eur J Cancer, 7, 471.
  25. Fountzilas G, Ciuleanu E, Bobos M, et al (2012). Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: A randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Ann Oncol, 23, 427-35. https://doi.org/10.1093/annonc/mdr116
  26. Hareyama M, Sakata K, Shirato H, et al (2002). A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer, 94, 2217-23. https://doi.org/10.1002/cncr.10473

Cited by

  1. Comparison of Radical Cystectomy and Chemoradiotherapy in Patients with Locally Advanced Bladder Cancer vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6519
  2. A Retrospective Study of Clinicoepidemiological Aspects of Nasopharyngeal Cancer at NCI-Cairo (2000-2010) vol.06, pp.11, 2015, https://doi.org/10.4236/jct.2015.611105
  3. Effect of Prolonged Radiotherapy Treatment Time on Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma vol.10, pp.10, 2015, https://doi.org/10.1371/journal.pone.0141332
  4. Comparison of Three Different Induction Regimens for Nasopharyngeal Cancer vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.59
  5. Progress and Challenges in Chemotherapy for Loco-Regionally Advanced Nasopharyngeal Carcinoma vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.4825
  6. The long-term outcomes of alternating chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multiinstitutional phase II study vol.4, pp.8, 2015, https://doi.org/10.1002/cam4.469
  7. Progression of understanding for the role of Epstein-Barr virus and management of nasopharyngeal carcinoma vol.36, pp.3, 2017, https://doi.org/10.1007/s10555-017-9693-x
  8. Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study vol.79, pp.6, 2017, https://doi.org/10.1007/s00280-017-3297-6